Qritive develops diagnostic tools. It integrates artificial intelligence and helps clinicians examine microscopy images and text from patient data. It allows medical practitioners to identify cancer quickly with the help of natural language processing. It develops Pantheon an artificial intelligence (AI)-driven ecosystem transforming pathology. The company was founded in 2017 and is based in Singapore, Singapore.
Qritive's Product Videos
ESPs containing Qritive
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology — oncology diagnostics market digitizes and obtains high-resolution images of cancerous tissue samples. These digital images can be easily stored, shared, and accessed remotely by pathologists, enabling more efficient collaboration and second opinions. The market includes various hardware and software solutions for scanning, storing, analyzing, and managing digital pathology …
Qritive's Products & Differentiators
Pathology Lab workflow management tool
Research containing Qritive
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Qritive in 1 CB Insights research brief, most recently on Aug 10, 2023.
Expert Collections containing Qritive
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Qritive is included in 3 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Latest Qritive News
Mar 20, 2023
AI will be integrated to increase pathologists' efficiency. Singapore-headquartered Qritive has integrated its AI modules with US-based Corista's image management platform DP3. According to a press statement, the combined solution leverages AI to screen for both prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis. It allows pathologists to prioritise and grade specific cases while improving the detection of hard-to-diagnose cancers. It also enables pre-reviewed AI analysis of digital pathology images utilising any whole slide image scanning device and LIS. Corista's DP3 is a DICOM-compliant pathology software that enables voice collaborations, remote case reviews, and global consults. It can integrate with either in-house or commercially available image analysis systems and features a proprietary LIS Connector. WHY IT MATTERS Pathology departments have been overwhelmed with huge demands for diagnostic screening which rose with a rapidly ageing population, a growing incidence of chronic diseases, and the emergence of various epidemics. Integrating AI into pathology workflow has the potential to raise pathologists' efficiency. It delivers high-quality diagnoses while helping free up pathologists' time to focus on more complex cases. "Our partnership with Qritive will advance the use of [AI] applications to support the growing demands on pathologists to keep up with the pace of their workloads and the challenges of cancer diagnosis," said Liz Wingard, CEO and co-founder of Corista. "Corista's image management system combined with the assistive power of Qritive's AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision," Qritive CEO and co-founder Aneesh Sathe claimed. THE LARGER TREND In the same week, Qritive also announced the launch of its latest AI module for prostate cancer diagnosis. Called QAi Prostrate, the software module analyses whole slide images of prostate core needle biopsies, identifies prostatic adenocarcinoma region, and segments and classifies them into benign and malignant areas. It also provides a detailed summary explaining the tumour size and percentage for each slide or region of interest. The module can be integrated with any standard digital pathology system, as well as with existing workflows using an open API interface through customisable middleware. At the start of the year, Qritive raised $7.5 million in a funding round, which was intended to support its global expansion, regulatory approval attempts, and development of more AI imaging analysis solutions. Tags:
Qritive Frequently Asked Questions (FAQ)
When was Qritive founded?
Qritive was founded in 2017.
Where is Qritive's headquarters?
Qritive's headquarters is located at 71 Ayer Rajah Crescent, Singapore.
What is Qritive's latest funding round?
Qritive's latest funding round is Seed VC.
How much did Qritive raise?
Qritive raised a total of $7.51M.
Who are the investors of Qritive?
Investors of Qritive include MassMutual Ventures, Exfinity Venture Partners, Seeds Capital, India Edison Accelerator, India-Sweden Healthcare Innovation Centre and 7 more.
Who are Qritive's competitors?
Competitors of Qritive include Ibex and 5 more.
What products does Qritive offer?
Qritive's products include Pantheon and 2 more.
Compare Qritive to Competitors
Paige delivers artificial intelligence (AI) integrated digital diagnostics solutions and biomarkers for pathologists, oncologists, and the cancer diagnostics research and development community. It works with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The company was founded in 2017 and is based in New York, New York.
TRIBVN Healthcare is a company focused on the digital transformation of cancer diagnosis within the healthcare sector. The company offers innovative solutions for the management, analysis, and sharing of cellular images, leveraging artificial intelligence technologies to support diagnostic decision-making and scientific evaluation. Its primary customers include diagnostic laboratories, pharmaceutical companies, and biotech organizations. It was founded in 2011 and is based in Paris, France.
Aiosyn is a medical software company that develops AI-powered pathology solutions. It develops computational pathology technology to facilitate decision-making in both drug development and clinical diagnostics. The company provides perspectives that lead to patient identification and stratification in drug development programs. It provides solutions for biotech, pharma, and diagnostics companies. Aiosyn was founded in 2021 and is based in Nijmegen, Netherlands.
Mechanomind is an artificial intelligence (AI) image recognition for cancer diagnostics. It applies computer vision and deep learning to solve the problem of accessibility, accuracy, speed, and cost of cancer diagnostics worldwide. The company was founded in 2015 and is based in New York, New York.
Deciphex is a company that focuses on the development of software applications in the pathology industry. The company's main offerings include digital pathology solutions and artificial intelligence tools designed to enhance the productivity of pathologists and improve the efficiency of pathology services. Deciphex primarily serves the healthcare and pharmaceutical sectors. It was founded in 2017 and is based in Dublin, Ireland.
Azra AI software interprets unstructured data to identify and triage oncology patients who need treatment and follow-up care. Azra AI's product provides enhanced quality of care in the clinical setting, increases time with patients, identifies at-risk patients, provides real time business analytics of patient flow, and increases patient retention. The firm was founded in 2022 and is based in Franklin, Tennessee.